Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

12 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 M4\4fGN6fG:2b4jpZ{BCe3OjeR?= NIPQNoIyOCCwTR?= NUHYe3dWPzJiaB?= NGi0RoNFVVOR NU\pdWNZWG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NV:2fo1LOjR7MEC4O|M>
HT-29 M{\PTGN6fG:2b4jpZ{BCe3OjeR?= NUDnSHRuOTBibl2= M{HkbFczKGh? NVX2eYw3TE2VTx?= MoDXVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 M3fSVFI1QTByOEez
HT-29 MUHDfZRwfG:6aXOgRZN{[Xl? MXuxNEBvVQ>? MWq3NkBp NG\wSIFFVVOR M4W4e3BwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NVrxPFUxOjR7MEC4O|M>
PC3 NYT4TXA1U2mwYYPlJGF{e2G7 MmLvNVAxKG6P NWjRXlhJOSCq MkfYSG1UVw>? MV3Qc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?= M2L2T|IyQTd6Nkiz
PC3 MXfLbY5ie2ViQYPzZZk> NXT5RXA5OTByIH7N NGPZV4EyKGh? M37qSWROW09? MV;Ec4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? Mmj6NlE6Pzh4OEO=
PC3 NXrKfZZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jkflEvPSEQvF2= MVSxJIg> NUP4T2c2TE2VTx?= MnizTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6P NYLjNoVFOjF7N{i2PFM>
HEK293 Ml;ZSpVv[3Srb36gRZN{[Xl? M2XQclExOCCwTR?= M4L1OFghcA>? Mon0SG1UVw>? M{jn[WlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= NYTldJhXOjF3M{mzNFE>
BT-20 NHXhe4RMcW6jc3WgRZN{[Xl? NXuz[GNNOjBizszN MYfEUXNQ M3jFb2Rw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:w M37UdVIyOzV|NUWx
U937 M1XPdWFvfGmkYXP0[ZJq[WxiQYPzZZk> NXHIUmlqPTBizszN MmjzOFghcA>? MnLBSG1UVw>? NFvP[JFKdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO= MXOyNVE1OjFyNh?=
U937 M1PPbmFvfGmkYXP0[ZJq[WxiQYPzZZk> MlrCOVAh|ryP MYi0PEBp M{jH[mROW09? NIXhS|NFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy| NUPpZlBUOjFzNEKxNFY>
U937 NHvwb2ZCdnSrYnHjeIVzcWGuIFHzd4F6 NUn2bWx{PTBizszN M3jPSlQ5KGh? M3\lNWROW09? NHjpWG1Fd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>? M1r2OFIyOTR{MUC2
MCF-7 MmXxRZV1d3CqYXf5JGF{e2G7 NUHve49YOzBibl2= MXS0JIg> NX;ONGF4TE2VTx?= NG[4d5RKdmS3Y3XzJIF2fG:yaHHnfS=> MmTaNlAxOjhzM{S=
U87MG MXjLbY5ie2ViQYPzZZk> M1TqUVEh|ryP M{X1ZlYhcA>? M{jmUWROW09? NEj2V3ZRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?= Mk\jNVk5PDh2MES=
U87MG MVzLbY5ie2ViQYPzZZk> M4DBWFEh|ryP NH;nc2g3KGh? M1rtdGROW09? MnzOVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= M1H4R|E6QDR6NEC0
U87MG MX7LbY5ie2ViQYPzZZk> MkG0NUDPxE1? MmHtOkBp MlrkSG1UVw>? M1HN[2Rw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w MmK0NVk5PDh2MES=
U87MG MmTST4lv[XOnIFHzd4F6 M{nzUlEh|ryP NFvwfXU3KGh? MlSzSG1UVw>? M2rXZ2Rw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>? NUDPOGdCOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb MnmwRZV1d3CqYXf5JGF{e2G7 MmTsNE4zKM7:TR?= MlriNlQhcA>? M{TJNGROW09? NWq5S5RzUW6mdXPld{BifXSxcHjh[5k> MXuxPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 MkD1RZV1d3CqYXf5JGF{e2G7 NGnCVGwxNjJizszN MmLlNlQhcA>? M{nmcGROW09? NXT3TpBCUW6mdXPld{BifXSxcHjh[5k> NYHISVZKOTh|OUG5OFk>
H4 M2X1bGZ2dmO2aX;uJGF{e2G7 MYKwMlIh|ryP MVyyOEBp NFXHfFBFVVOR MWTJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz MWOxPFAzPDV6NB?=
HeLa M4\jdWZ2dmO2aX;uJGF{e2G7 NVPuUGE1OTByIH7N M3fESVM3KGh? MoL6SG1UVw>? NY\ob2ZKUW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? M{LxPFE4PTZ|M{i1
HeLa MoPKSpVv[3Srb36gRZN{[Xl? NEjjdIEyODBibl2= NHWwWHM{PiCq MnzvSG1UVw>? NHvScmRKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? MX[xO|U3OzN6NR?=
HeLa M4\qTWZ2dmO2aX;uJGF{e2G7 NEjyXVMyODBibl2= M3v4UVM3KGh? NEWxWlhFVVOR NVLCNHM{UW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v M1XYZVE4PTZ|M{i1
SYF MXvGeY5kfGmxbjDBd5NigQ>? NH;iTZMyODBibl2= Mn;jNlQhcA>? MVLEUXNQ M4TU[Glv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> MYKxO|U3OzN6NR?=
SYF NX3NcXVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvBNVAxKG6P MVmyOEBp MWTEUXNQ NVHn[pdNUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> NVTZTY8xOTd3NkOzPFU>
HEK293T MlXCRY51cX[rcnHsJGF{e2G7 NGjzNpcyKG6P MmKwOEBl NX3pVoo{TE2VTx?= NV;aRpdmUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> M{fOTVE4PDh3NUCx
HEK293T MVjBcpRqfmm{YXygRZN{[Xl? NHfncZkyKG6P M3jyclQh\A>? NYK5O2dWTE2VTx?= M4f1U2lv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N MnHlNVc1QDV3MEG=
PBMC MnrlSpVv[3Srb36gRZN{[Xl? NXvVSJltOSCwTR?= NXXnbZBvOTRiZB?= MX\EUXNQ NVTqR5IyWmWmdXPld{BES1J3IHTlcpNqfHl? NEj2SW8yPzR6NUWwNS=>
PBMC NFHiUnVHfW6ldHnvckBCe3OjeR?= NVjtcHpnOSCwTR?= MYKxOEBl NWLoUGVzTE2VTx?= MoDwSI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> NUTvdoJqOTd2OEW1NFE>
HEK293 cells NVradXRYU2mwYYPlJGF{e2G7 M1rMWlUxKG6P NU\QSG03PDVibXnu M1LqPGROW09? MoTkTY5pcWKrdIOgcXRQWiCtaX7hd4Uh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNUBvVQ>? MV6xO|M2ODl3Mx?=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NGjDdFhHfW6ldHnvckBCe3OjeR?= NIDtd5IyODBibl2= NXHKTG8xPCCq M17LWmROW09? NUXXRpp1UW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? M4izO|E4OTJ6Mk[y
Human mixed lymphocyte NEfHPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXO[no2KG6P NHK1TXNFVVOR MlHWTWM2OD1zLk[gcm0v M1TURlE3OTh3OE[1
Lewis rat lymph node cells NITk[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXHOUDPxE1? MYLEUXNQ NHnmPI1KSzVyPUKuOkDPxE1? NFL2UFQyPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice M3XCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofDNVAhdk1? MmPRO|IhcA>? NYj3c3F6TE2VTx?= NGLsWHZKdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N MkTFNVAxOjF7NEi=
MRK-nu-1 NW\zSpJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj1WWFGUUN3ME2wMlg1PSCyTR?= NGXxdnBUSU6JRWK=
OCUB-M MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTVwMkSgdG0> NGXqSnpUSU6JRWK=
SF539 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofnTWM2OD1zMT62JJBO NGHQe45USU6JRWK=
ES4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vFb2lEPTB;MkGuOUBxVQ>? MnvhV2FPT0WU
RL95-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3WTWM2OD1zMEegdG0> NXjVZoFWW0GQR1XS
LC-2-ad M{H4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTR{MzDwUS=> NI\5fI1USU6JRWK=
Daudi NX7QZo0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPqd25KSzVyPUSzOEBxVQ>? NH3QTlJUSU6JRWK=
NTERA-S-cl-D1 NXzRS5JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S3NWlEPTB;NESzJJBO MVXTRW5ITVJ?
OS-RC-2 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XFWmlEPTB;NkWyJJBO NE[zR4lUSU6JRWK=
VA-ES-BJ NYOyRXFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTsTWM2OD15MkOgdG0> MlHsV2FPT0WU
GR-ST NWTEZpZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrCVFJrUUN3ME24OFYheE1? MVnTRW5ITVJ?
SW872 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\ZeGlEPTB;OES2JJBO M1\Hb3NCVkeHUh?=
NOS-1 NIL5NGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK4UZFoUUN3ME24O|EheE1? Ml33V2FPT0WU
MC116 M2HONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTl6NTDwUS=> NXzEVXM{W0GQR1XS
NCI-H1355 NGe2ZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zrS2lEPTB;MT6wNUBvVQ>? MnHoV2FPT0WU
RPMI-8226 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHuTWM2OD1zLkG5JI5O NEezPYpUSU6JRWK=
TE-15 NUDlV4ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC1TWM2OD1zLkO2JI5O M1LwWnNCVkeHUh?=
Ramos-2G6-4C10 M3zWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrGTWM2OD1zLkS2JI5O MXfTRW5ITVJ?
KU812 M4jxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XYd2lEPTB;Mj6wNUBvVQ>? M4fX[3NCVkeHUh?=
EW-1 NXnyN4RqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnHSVBKSzVyPUKuNVchdk1? NHzaVnlUSU6JRWK=
KS-1 NInsb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\JTWM2OD1{LkS1JI5O M4Pk[nNCVkeHUh?=
SK-LMS-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJwNEmgcm0> M4\DNHNCVkeHUh?=
TGBC1TKB NHmx[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnOTWM2OD1{Lk[5JI5O Mmn6V2FPT0WU
TE-6 MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmzdGdMUUN3ME2yMlc4KG6P M3\KbnNCVkeHUh?=
ETK-1 NYPZZpFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvYcpdKSzVyPUKuPFIhdk1? M2XGbHNCVkeHUh?=
BE-13 MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3QXFZoUUN3ME2yMlk6KG6P Mn\6V2FPT0WU
A3-KAW NYfF[|k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zqXWlEPTB;Mj65PUBvVQ>? NYf1O2RZW0GQR1XS
TE-10 NGi5bIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7xe4ZKSzVyPUOuN{BvVQ>? NHrGdYxUSU6JRWK=
DOHH-2 MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTNwM{Wgcm0> M{ntOXNCVkeHUh?=
ES6 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfPZ2JKSzVyPUOuOFMhdk1? MV7TRW5ITVJ?
OPM-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfNTWM2OD12LkG1JI5O M1;H[nNCVkeHUh?=
SH-4 NXTYNmFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHLfHJKSzVyPUSuN|Qhdk1? MY\TRW5ITVJ?
NB13 NFjyUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnrW5ZVUUN3ME20MlM3KG6P M1zodXNCVkeHUh?=
HUTU-80 M4XZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTRwNEKgcm0> NEnIZWZUSU6JRWK=
CCRF-CEM MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\VW2lEPTB;ND65OEBvVQ>? M2jPW3NCVkeHUh?=
TGBC24TKB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO4TWM2OD13LkWxJI5O NXTTOGNzW0GQR1XS
697 NXvsfIlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorqTWM2OD14LkK4JI5O MXHTRW5ITVJ?
J-RT3-T3-5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PNWGlEPTB;Nj60OkBvVQ>? M3LGZnNCVkeHUh?=
KALS-1 NXj2VYxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTZwNU[gcm0> NWXVUXNtW0GQR1XS
no-10 NFG2VoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTdwMkmgcm0> NWn1b3ZoW0GQR1XS
SK-NEP-1 M2PFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLLTWM2OD16Lke5JI5O NYXQZYFEW0GQR1XS
L-540 NH;0eVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjseHl5UUN3ME2xNE41OiCwTR?= NGjYOHlUSU6JRWK=
JiyoyeP-2003 NYfRN2NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j2VWlEPTB;MUCuPVQhdk1? NWDXbWROW0GQR1XS
HH NUnReXZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\NZ2lEPTB;MUGuN|khdk1? MV\TRW5ITVJ?
SR NIjiWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuyOGhKSzVyPUGxMlQ2KG6P NUTOV3d1W0GQR1XS
QIMR-WIL MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vDRWlEPTB;MUGuPFUhdk1? NILPOGhUSU6JRWK=
A4-Fuk M{Pwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF|LkGyJI5O M33lPHNCVkeHUh?=
CESS NYLNU29VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF|LkGzJI5O NFz2XXNUSU6JRWK=
KE-37 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfnXWtKSzVyPUG2MlA4KG6P M2PlW3NCVkeHUh?=
SK-UT-1 M{jLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv4TW5iUUN3ME2xOk45OSCwTR?= MX3TRW5ITVJ?
SIG-M5 M2PHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH34eHFKSzVyPUG3MlI2KG6P M2X6d3NCVkeHUh?=
HT MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nDNGlEPTB;MUeuOkBvVQ>? MnLxV2FPT0WU
DEL Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDl[3lLUUN3ME2xO{46QSCwTR?= Mn\sV2FPT0WU
SK-PN-DW MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ETWM2OD1{MD6yN{BvVQ>? NFzxS|JUSU6JRWK=
RPMI-8402 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y3fmlEPTB;MkGuO|chdk1? M{fHO3NCVkeHUh?=
RPMI-6666 M4DT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:ySFVKSzVyPUK0MlQzKG6P NF[2RlFUSU6JRWK=
NCI-H720 M4DXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\FNFAzUUN3ME2yOU41OSCwTR?= NWfmV2RUW0GQR1XS
EW-16 NGjnPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInFeG1KSzVyPUK2Mlg4KG6P MXvTRW5ITVJ?
BL-70 NFnndJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y2PGlEPTB;MkiuN|ghdk1? MYTTRW5ITVJ?
SF126 NFrwUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z2O2lEPTB;M{CuN|ghdk1? NETpfXRUSU6JRWK=
BC-1 NIXH[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzw[I9KSzVyPUOxMlI3KG6P MXXTRW5ITVJ?
MHH-PREB-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD3R|hWUUN3ME2zNk41PCCwTR?= MoS0V2FPT0WU
A101D MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTN{Lk[yJI5O Mnu5V2FPT0WU
NMC-G1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTN|Lk[3JI5O M1vQcnNCVkeHUh?=
LB1047-RCC NHPLSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDETWM2OD1|ND62PUBvVQ>? NFKycHZUSU6JRWK=
EM-2 NITROHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPkVGhKSzVyPUO4MlU{KG6P NIrCfI5USU6JRWK=
COLO-684 NGq0Z|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrqTWM2OD1|OT64JI5O MmHZV2FPT0WU
Becker M3vk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jRfWlEPTB;NEGuNFUhdk1? MojxV2FPT0WU
BL-41 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTR|Lk[2JI5O Mlv2V2FPT0WU
MDA-MB-134-VI Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DRXWlEPTB;NESuNFIhdk1? NVnWOIZpW0GQR1XS
L-363 MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXmycXdlUUN3ME20OE44OyCwTR?= M1zSWnNCVkeHUh?=
ECC4 NXz6WZlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\FTWM2OD12ND63PEBvVQ>? NH\rcJFUSU6JRWK=
A388 NF7QSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTzZ3hkUUN3ME20OE45OiCwTR?= NXzFZWZsW0GQR1XS
HEL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPIXWRKSzVyPUS5Mlc6KG6P NGSwd2xUSU6JRWK=
RKO MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTVyLkK5JI5O MlH4V2FPT0WU
KINGS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHhTWM2OD13MT61OUBvVQ>? NW\RVXhLW0GQR1XS
EB-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W4VWlEPTB;NUKuOlchdk1? NYq2T2lDW0GQR1XS
ARH-77 M3TWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH6dmZKSzVyPUWyMlghdk1? M1rySnNCVkeHUh?=
GCIY MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnvTWM2OD13Mz60OkBvVQ>? NV\odI0{W0GQR1XS
NCI-H1304 NUPlWGpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTV5LkKyJI5O M3PySXNCVkeHUh?=
KARPAS-299 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF74eG5KSzVyPU[xMlgzKG6P NXX5U216W0GQR1XS
IA-LM NH36RVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT6c4dpUUN3ME22PE4yOyCwTR?= M4Ta[HNCVkeHUh?=
GI-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\nVWlEPTB;N{CuN|khdk1? NXjqdWlbW0GQR1XS
TE-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP0TWM2OD15Nz6xO{BvVQ>? MX\TRW5ITVJ?
LS-411N MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fCdmlEPTB;N{euOVchdk1? NFGxUlZUSU6JRWK=
no-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknCTWM2OD16Mz6yOEBvVQ>? NYHFdZhOW0GQR1XS
MV-4-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjMXmw{UUN3ME24N{44OyCwTR?= MkO1V2FPT0WU
BV-173 M4H0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LXOGlEPTB;OEOuPVchdk1? M{iyOXNCVkeHUh?=
CMK NGKwOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTh2LkG2JI5O M1nRUHNCVkeHUh?=
LC4-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG3TWM2OD16Nj63NkBvVQ>? MknMV2FPT0WU
COR-L279 M2j4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTh5LkK1JI5O NEDBdHZUSU6JRWK=
NCI-H209 NWHQVoRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTh5LkSxJI5O NGLLVHFUSU6JRWK=
Raji M3nH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXwOHhKSzVyPUi5MlczKG6P MmXUV2FPT0WU
LB996-RCC NH7LfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq2UmJKSzVyPUmzMlQ{KG6P NV3aeJVSW0GQR1XS
NCI-H526 NVnqXotKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvHTWM2OD17Mz61PUBvVQ>? NV\xd5RvW0GQR1XS
KGN NFvGWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrv[XFKSzVyPUm2MlI6KG6P NUTXU2FRW0GQR1XS
MOLT-4 M1\EXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTs[ohoUUN3ME25Ok44QSCwTR?= MW\TRW5ITVJ?
PF-382 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q4Z2lEPTB;OU[uO|khdk1? MlnOV2FPT0WU
BC-3 M1\0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDidox[UUN3ME25PU4yQCCwTR?= NE\Y[YxUSU6JRWK=
KARPAS-422 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTyc45{UUN3ME2xNFIvODlibl2= M1zJNHNCVkeHUh?=
SBC-1 NEfMOVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Pue2lEPTB;MUC3Mlc2KG6P NEWzPVZUSU6JRWK=
LC-1F MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDyTWM2OD1zMEiuNFUhdk1? M4rtPHNCVkeHUh?=
GB-1 MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHDTWM2OD1zMEmuNFIhdk1? M1XoZnNCVkeHUh?=
SNB75 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXHOlM6UUN3ME2xNVkvPjlibl2= M1fzU3NCVkeHUh?=
BB65-RCC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nMZ2lEPTB;MUG5Mlk{KG6P NV30PGVoW0GQR1XS
NCI-N87 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;od4J6UUN3ME2xNlEvQThibl2= Ml;lV2FPT0WU
IST-MEL1 M{C4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPmWYZKSzVyPUGyNk4{QCCwTR?= NFrCdJlUSU6JRWK=
HOP-62 NF;1eGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDvcZlKSzVyPUGyOk45QSCwTR?= MnH5V2FPT0WU
ACN MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T6VGlEPTB;MUS2Mlc2KG6P MUDTRW5ITVJ?
DMS-114 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7STWM2OD1zNUCuOlchdk1? MkjrV2FPT0WU
MLMA NFXjVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3hUWxRUUN3ME2xOVkvQDhibl2= Mn[4V2FPT0WU
HT-144 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXyOXlKSzVyPUG2OU41OyCwTR?= M2XwPXNCVkeHUh?=
C2BBe1 NX;BWoVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnRTWM2OD1zNkeuO|Yhdk1? M2LpcnNCVkeHUh?=
L-428 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF5Nz63JI5O Mn\EV2FPT0WU
DU-4475 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF6Nz62PEBvVQ>? MmLWV2FPT0WU
CP67-MEL NFXxXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTF7OT6zPEBvVQ>? NEP2dlBUSU6JRWK=
MEG-01 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[2bJVxUUN3ME2yNFEvQTZibl2= NFTnfotUSU6JRWK=
IST-SL2 MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJyOD62N{BvVQ>? NXzlSVB6W0GQR1XS
ES8 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\UOmxjUUN3ME2yNlUvQTRibl2= NE\UO5dUSU6JRWK=
COLO-800 NVvNe49lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K3[WlEPTB;MkO1MlI5KG6P MYPTRW5ITVJ?
MFH-ino NXLp[phLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX4TWM2OD1{M{WuPFQhdk1? MlTiV2FPT0WU
OVCAR-4 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHNTWM2OD1{M{euNlQhdk1? NXjqbmpqW0GQR1XS
PSN1 NH3oWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn4U251UUN3ME2yOFIvPzFibl2= M3vheHNCVkeHUh?=
EW-12 NWeweVVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJ2Mz6xJI5O NFf1TIhUSU6JRWK=
HCC1599 NGTi[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LibWlEPTB;Mk[xMlQ4KG6P MoLnV2FPT0WU
SJSA-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XlS2lEPTB;MkexMlQ3KG6P NYfBPWJyW0GQR1XS
ST486 NWfGRoFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PDbWlEPTB;Mkm2MlE1KG6P M2LSUnNCVkeHUh?=
NOMO-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNyMD6yNUBvVQ>? MXPTRW5ITVJ?
MN-60 NEPZe5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;BVnhKSzVyPUOwOU4{OiCwTR?= NYnWUm9IW0GQR1XS
HCC1187 NYfFbpNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XXdmlEPTB;M{C3MlI2KG6P MnGwV2FPT0WU
SW982 NWn1bnJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mzVGlEPTB;M{G0Mlc2KG6P MmDNV2FPT0WU
LB647-SCLC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTN{OD63NUBvVQ>? NHfvXXJUSU6JRWK=
HC-1 NGHOc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:4SmlEPTB;M{O1MlUhdk1? MW\TRW5ITVJ?
EHEB NXrBfWUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnFbmtLUUN3ME2zN|cvPTJibl2= MnGxV2FPT0WU
TUR NXL4Oop[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzSTWM2OD1|NkOuPVUhdk1? MVzTRW5ITVJ?
LU-139 NYHM[5pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXObZVSUUN3ME2zO|gvODJibl2= NYjaZW5HW0GQR1XS
NB1 M4Pl[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTN6ND60OUBvVQ>? MXvTRW5ITVJ?
BB30-HNC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD4U3NtUUN3ME2zPFgvOzJibl2= MWLTRW5ITVJ?
HAL-01 NX;ERXNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTN6OT6yOkBvVQ>? NEjXOGJUSU6JRWK=
K5 M4LIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe2XlVKSzVyPUSxNU4{PyCwTR?= M{fMOXNCVkeHUh?=
MZ2-MEL MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NECwe2JKSzVyPUSxN{43PCCwTR?= M1nnV3NCVkeHUh?=
RXF393 NV7WNFg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[0TWM2OD12MU[uOFUhdk1? NVz2XoYyW0GQR1XS
NCI-H1648 M1XBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rhVmlEPTB;NEG3MlU{KG6P M1\qcnNCVkeHUh?=
TE-12 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHhOpRpUUN3ME20N|QvOjZibl2= M2Xv[XNCVkeHUh?=
EoL-1- NH\He|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\oTWM2OD12M{euPVghdk1? M{jCTnNCVkeHUh?=
JAR M2rSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vSVGlEPTB;NEO4MlYzKG6P MUfTRW5ITVJ?
DSH1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nMPGlEPTB;NEW4MlkyKG6P MmDZV2FPT0WU
NCI-H187 M{fwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLwTWM2OD12NkKuPFEhdk1? M2LteXNCVkeHUh?=
HCE-4 M4\Hc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTsTWM2OD12N{euOlYhdk1? NFTq[JdUSU6JRWK=
8-MG-BA NYrQfm1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfnN5FwUUN3ME21PFEvPTJibl2= NVnmdGpuW0GQR1XS
KLE MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjQNHA6UUN3ME21PFUvOiCwTR?= M{jq[nNCVkeHUh?=
KNS-42 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fjTGlEPTB;NUi2MlgyKG6P M37BXXNCVkeHUh?=
MSTO-211H NEjHNFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTZyOT63OEBvVQ>? MoXhV2FPT0WU
GDM-1 NFzaRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7yVGNKSzVyPU[xOE4xQSCwTR?= MVzTRW5ITVJ?
TE-1 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTZ2Nj6xNkBvVQ>? Mmf4V2FPT0WU
BT-474 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTZ2Nz6wOkBvVQ>? NVe5ZmZKW0GQR1XS
KARPAS-45 NWDqXog2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnpTWM2OD14NEeuOkBvVQ>? NXPJNmUxW0GQR1XS
MOLT-16 MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK4S|hKSzVyPU[0O{46OyCwTR?= NIfZd5pUSU6JRWK=
KURAMOCHI MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnkfZdKSzVyPU[1O{42OSCwTR?= MluxV2FPT0WU
K-562 NVHrVFRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDCfYFKSzVyPU[2PU42OSCwTR?= NFfTN4ZUSU6JRWK=
EKVX NVzzUGVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTkZop5UUN3ME22O|IvPzFibl2= NUfuT3JSW0GQR1XS
GAK M1;r[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTZ5NT6zJI5O MUDTRW5ITVJ?
NCI-SNU-5 MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK1VFNKSzVyPU[5NE4xOSCwTR?= NWDZOXNMW0GQR1XS
NCI-H2126 NV64foVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr5[JNzUUN3ME23NlYvQDdibl2= NXHodW1GW0GQR1XS
CTV-1 NYX5T|Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTd2ND65JI5O MXHTRW5ITVJ?
SW962 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfJbWpkUUN3ME23OFgvPDRibl2= NHu2dWlUSU6JRWK=
MONO-MAC-6 NIfSdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTd3Nj65N{BvVQ>? MlPtV2FPT0WU
NCI-H748 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTd3OD65PUBvVQ>? MkGwV2FPT0WU
NCI-H524 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTd6MD63N{BvVQ>? MoPkV2FPT0WU
LS-123 NYnD[XhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTd7NT62PUBvVQ>? NEjVbm5USU6JRWK=
NB7 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjURWtKSzVyPUixOE4yPCCwTR?= NEPYbWxUSU6JRWK=
LS-1034 NEHPcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPP[2ZKSzVyPUiyPE46QCCwTR?= MXrTRW5ITVJ?
TE-5 NIDBRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fjcWlEPTB;OEizMlU3KG6P MWDTRW5ITVJ?
A704 NFrYSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTh7OT6xOUBvVQ>? M{f2VXNCVkeHUh?=
TK10 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTpTWM2OD17MU[uNFMhdk1? M4fz[XNCVkeHUh?=
NCI-H345 M{DObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO1TWM2OD17NEOuNlIhdk1? NFuxVlhUSU6JRWK=
CGTH-W-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDrUXZKSzVyPUm0PE4yOyCwTR?= NF;FR2pUSU6JRWK=
NCI-H510A MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXuV|FKSzVyPUm4OU4yOiCwTR?= NF7hWldUSU6JRWK=
NCI-H1963 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwMEOyPVIh|ryP MkS4V2FPT0WU
SCC-3 MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zIT2lEPTB;MT6wN|QyPCEQvF2= MWLTRW5ITVJ?
EW-11 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXpUWxKSzVyPUGuNFg4PDNizszN M3;tRXNCVkeHUh?=
CPC-N NYjTcoNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLIdXpKSzVyPUGuNFg5KM7:TR?= MoLNV2FPT0WU
NCI-H1417 M2rrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX6OVVKSzVyPUGuNVIzPiEQvF2= M4Wzb3NCVkeHUh?=
DG-75 M{DOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHySnRKSzVyPUGuNVYzQDVizszN MYLTRW5ITVJ?
HD-MY-Z Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjZSGdDUUN3ME2xMlE3PDF4IN88US=> MojZV2FPT0WU
ATN-1 NYXqWnZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\NWJhzUUN3ME2xMlI3OjB7IN88US=> M3v1e3NCVkeHUh?=
KM-H2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwMk[0NFgh|ryP NFX2SGpUSU6JRWK=
NCI-H2081 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS1c|RJUUN3ME2xMlI3PjN5IN88US=> NV;CNVdDW0GQR1XS
HL-60 NXS5WoQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HuV2lEPTB;MT6yOlk2QSEQvF2= NF\mb49USU6JRWK=
DB MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwMkeyOFIh|ryP Ml\TV2FPT0WU
NCI-H1522 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnTcYd3UUN3ME2xMlI5QDh5IN88US=> M4nx[XNCVkeHUh?=
AM-38 NXu5T5p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUCwfVJxUUN3ME2xMlMxPzJizszN MnrFV2FPT0WU
NCI-H446 M17nTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoSwTWM2OD1zLkOyNVIyKM7:TR?= MkDHV2FPT0WU
SU-DHL-1 NXjIVpl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DtO2lEPTB;MT6zNlgxOSEQvF2= MVnTRW5ITVJ?
NH-12 NVj4fXE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL2VItwUUN3ME2xMlM3Ozd2IN88US=> NYr5[2w2W0GQR1XS
DMS-79 M4\4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXixdIpPUUN3ME2xMlM3QDZ4IN88US=> M2r1WnNCVkeHUh?=
NCI-H716 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MomwTWM2OD1zLkO4PVg3KM7:TR?= NF;GWGJUSU6JRWK=
ML-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3j[4VvUUN3ME2xMlQyPTJ7IN88US=> M2nyXnNCVkeHUh?=
NB10 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHS[JJKSzVyPUGuOFY3OzJizszN NUS1fGRMW0GQR1XS
ONS-76 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fpTWlEPTB;MT61N|U3QSEQvF2= MX;TRW5ITVJ?
LOUCY NU\wSWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwNUS2OVch|ryP Mo\3V2FPT0WU
SCLC-21H NI\BSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnZSI1yUUN3ME2xMlU5PTh{IN88US=> NHrRcXFUSU6JRWK=
TGW NIDOSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFwNkO5O|Uh|ryP NEPWTXJUSU6JRWK=
LXF-289 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zwXWlEPTB;MT63N|I3QCEQvF2= M2XWOnNCVkeHUh?=
BB49-HNC NEfGSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfFNYlKSzVyPUGuO|M2QDZizszN NED5PYhUSU6JRWK=
NCI-H747 NH7jXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz6TWM2OD1zLke1N|Q3KM7:TR?= M{KzUHNCVkeHUh?=
LU-165 Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\VZ2RKSzVyPUGuPFQ6QDZizszN M2e4XXNCVkeHUh?=
OMC-1 NYrrdphFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFwOUWwOlYh|ryP MULTRW5ITVJ?
RCC10RGB NH;kZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;1TXhKSzVyPUGuPVU5OTdizszN NWrONoN1W0GQR1XS
SW684 NV:2TGNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7LTWM2OD1zLkm2NFk6KM7:TR?= MVfTRW5ITVJ?
TE-8 NHLDWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\DcIJKUUN3ME2yMlA2PTV7IN88US=> NYW4[YQ3W0GQR1XS
SK-N-DZ MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml34TWM2OD1{LkGzNlc1KM7:TR?= MW\TRW5ITVJ?
EVSA-T MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK4TWM2OD1{LkG3N|E2KM7:TR?= Ml3sV2FPT0WU
KASUMI-1 NF22blhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\3WGlEPTB;Mj6xPFgyPSEQvF2= M2C4bnNCVkeHUh?=
NKM-1 NGi4T|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LnTWlEPTB;Mj6yOVQ4OiEQvF2= NHfxfWZUSU6JRWK=
CAL-148 M17vXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTtTWM2OD1{LkOzOlE1KM7:TR?= NGX6ZWFUSU6JRWK=
NCI-H64 NGfCTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrEfY1IUUN3ME2yMlM1OjN{IN88US=> NWfMbGRNW0GQR1XS
KNS-81-FD MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXYN3gyUUN3ME2yMlM3PjJizszN MmnlV2FPT0WU
KM12 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M360cGlEPTB;Mj60NFg{QSEQvF2= MVLTRW5ITVJ?
SW954 NXzSPYJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLzTWM2OD1{LkS3O|c6KM7:TR?= MVfTRW5ITVJ?
NCI-H1395 MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJwNUK2OFUh|ryP MV3TRW5ITVJ?
DJM-1 M{nOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvSb3BKSzVyPUKuOlA3OyEQvF2= NU\3S3JyW0GQR1XS
COLO-668 NUfIcW5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfMTWM2OD1{LkiyOlk2KM7:TR?= NELheYdUSU6JRWK=
NCI-H1436 NYDicFZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rKfWlEPTB;Mj64OVYyPSEQvF2= M3LyVHNCVkeHUh?=
LB2241-RCC NITCXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfURnJKSzVyPUKuPFY5OzlizszN NXrCUGJvW0GQR1XS
GT3TKB NXO4SlhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33vemlEPTB;Mj64PVA2PSEQvF2= M2jZ[HNCVkeHUh?=
COLO-824 NIHEc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJwOEm3Olgh|ryP MkiyV2FPT0WU
ES1 NXT6RodvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XMRWlEPTB;Mj64PVg4QSEQvF2= NXPRNXJxW0GQR1XS
LB771-HNC MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPmW5d6UUN3ME2yMlkxQTR4IN88US=> M{j0NXNCVkeHUh?=
GI-ME-N MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fJbmlEPTB;Mz6wNFkxPCEQvF2= M1;4cnNCVkeHUh?=
NALM-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfrcYhKSzVyPUOuNFA6OzNizszN M3XKSHNCVkeHUh?=
LU-134-A MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnGO2l2UUN3ME2zMlA2PDJ3IN88US=> MoSyV2FPT0WU
DMS-153 NWWwTJFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\6TWM2OD1|LkC1PFI1KM7:TR?= M3Ls[nNCVkeHUh?=
MZ1-PC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwMEmwO|gh|ryP NH3XTHVUSU6JRWK=
NCI-H1155 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzOTWM2OD1|LkGxOlEh|ryP MWXTRW5ITVJ?
CAS-1 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nrTWlEPTB;Mz6xN|cxPyEQvF2= MWDTRW5ITVJ?
D-502MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTNwMUSzPUDPxE1? NXX0[Y42W0GQR1XS
NCI-H2141 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjheWZKSzVyPUOuNVc1PTJizszN M2jnc3NCVkeHUh?=
NB6 NHHpdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTNwMUiyOVkh|ryP MULTRW5ITVJ?
NCCIT MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnIT5BjUUN3ME2zMlIyQDB7IN88US=> NHXJ[mpUSU6JRWK=
NB69 NFKwc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTNwM{G4PVEh|ryP NGTXcotUSU6JRWK=
JVM-2 NVKwU29pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNwM{[0N|Mh|ryP NUXtd3hsW0GQR1XS
K052 M3;1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn5SVhKSzVyPUOuN|c6PjhizszN M1ywZnNCVkeHUh?=
HCC2157 M4fDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LrWGlEPTB;Mz61N|IzQCEQvF2= NV;tV4FQW0GQR1XS
KMOE-2 Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO3VFNUUUN3ME2zMlU1OjR{IN88US=> NFjaUVZUSU6JRWK=
SF268 MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\DXoFqUUN3ME2zMlcyPTV2IN88US=> NXTWeJFlW0GQR1XS
CHP-126 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjtOmpKSzVyPUOuO|Y1PThizszN MYnTRW5ITVJ?
CP66-MEL M3zqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS0TWM2OD1|Lke5NFk1KM7:TR?= MXvTRW5ITVJ?
NCI-H69 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\OcVlOUUN3ME20MlAyQTN4IN88US=> MWfTRW5ITVJ?
A253 M4fLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK1RmJKSzVyPUSuNFIyODFizszN NW\GVWY6W0GQR1XS
NB14 NEPMOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHXTWM2OD12LkGwOFc6KM7:TR?= NIjoRWJUSU6JRWK=
NCI-H1694 M{HleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f1ZmlEPTB;ND6xN|EyOiEQvF2= NHWzZYdUSU6JRWK=
NCI-H2196 NGnEeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTRwMUexOlkh|ryP MVXTRW5ITVJ?
TE-9 MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\1TWM2OD12LkG3OVgzKM7:TR?= MWPTRW5ITVJ?
D-283MED M3\Rc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonvTWM2OD12LkG4PFQh|ryP M1OzWnNCVkeHUh?=
OCI-AML2 NFjYU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknyTWM2OD12LkG5OFg6KM7:TR?= M{TEXHNCVkeHUh?=
D-263MG M3v3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfuN2NKSzVyPUSuNlI6PjFizszN M3faTHNCVkeHUh?=
MPP-89 NVfCbmV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT6TWM2OD12LkK3N|A1KM7:TR?= MXHTRW5ITVJ?
LAMA-84 NV;nc4dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRwM{C0NlEh|ryP MW\TRW5ITVJ?
LB373-MEL-D NI\5fYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PwbWlEPTB;ND6zOlc5QSEQvF2= NG\kZ4RUSU6JRWK=
UACC-257 NHLZcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTRwM{m1N|Qh|ryP NGP1O2VUSU6JRWK=
MC-CAR NXnNVm5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonkTWM2OD12LkSzPVkh|ryP NHXDOIVUSU6JRWK=
COLO-320-HSR M3HBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTEXGlSUUN3ME20MlQ1PDJ5IN88US=> M4j6PXNCVkeHUh?=
P30-OHK NYP5RndwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXOe4tKSzVyPUSuOlY2QDFizszN NHOyZ5JUSU6JRWK=
UACC-812 NX\GTVZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme3TWM2OD12Lk[5NVYyKM7:TR?= MUnTRW5ITVJ?
CTB-1 M3LWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPrTWM2OD12LkexOVU2KM7:TR?= MX3TRW5ITVJ?
ALL-PO M3vOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TvU2lEPTB;ND64OFA4PyEQvF2= NEXPcIRUSU6JRWK=
SK-MEL-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XFNmlEPTB;ND64Olk2PSEQvF2= M4DkWXNCVkeHUh?=
TC-YIK M36zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVixR49NUUN3ME20Mlk4QTR{IN88US=> M2O5T3NCVkeHUh?=
NCI-H1882 M2TyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnaVGVKSzVyPUWuNFIxODFizszN MX7TRW5ITVJ?
MHH-CALL-2 MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTVwMEWwOFIh|ryP NVTTXXNTW0GQR1XS
U-87-MG NXnGb4FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHLeIZKSzVyPUWuNFk1PjZizszN M4L6PHNCVkeHUh?=
NCI-H1092 NGjnVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTVwMk[1OVUh|ryP M1zjSHNCVkeHUh?=
TE-441-T NV\EOohUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfkcGN2UUN3ME21MlI4QDJizszN MmjXV2FPT0WU
SK-MEL-1 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTVwMkmwOFQh|ryP NUjlZ4RKW0GQR1XS
EW-22 NU\3[YFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTVwMkm0OlYh|ryP MX3TRW5ITVJ?
MZ7-mel MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC1Vm02UUN3ME21MlQxPjlzIN88US=> MlrHV2FPT0WU
LP-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfPPFRuUUN3ME21MlQyOjlzIN88US=> NEn5eHlUSU6JRWK=
NCI-SNU-16 M1fnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTGRY5kUUN3ME21MlY1ODd2IN88US=> NV\0WXJGW0GQR1XS
LU-65 M{H0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDuOVhMUUN3ME21Mlc3Ozd|IN88US=> MXzTRW5ITVJ?
CW-2 NFvVWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkKwTWM2OD13Lki1PVU6KM7:TR?= M3TGfHNCVkeHUh?=
WSU-NHL M2\QeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXwZWR5UUN3ME21Mlk2OTd2IN88US=> MYXTRW5ITVJ?
IST-MES1 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmniTWM2OD13Lkm1OFQ{KM7:TR?= NEPxPWpUSU6JRWK=
U-266 NIf0cG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzBdINKSzVyPUWuPVgzODJizszN NFjic3VUSU6JRWK=
TALL-1 NI\ocm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTzTWM2OD14LkG0Olg5KM7:TR?= NVXrWJdjW0GQR1XS
Calu-6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfxNHRvUUN3ME22MlE2OzF4IN88US=> MW\TRW5ITVJ?
MMAC-SF MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL2TWM2OD14LkG4OVU3KM7:TR?= NV:1cXNyW0GQR1XS
NCI-H82 NWLOVnRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHFTWM2OD14LkKwOFg6KM7:TR?= NY\EVVdlW0GQR1XS
RS4-11 NGHob2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnlV|dPUUN3ME22MlI2QDl5IN88US=> MVrTRW5ITVJ?
SNU-C2B Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXHOGZKSzVyPU[uOFA6PjlizszN NIHHbpFUSU6JRWK=
BOKU NUPzR3RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLVOHdbUUN3ME22MlQ4PTl5IN88US=> MoPSV2FPT0WU
C8166 Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDscldKSzVyPU[uOVU6OTJizszN NGmwTYZUSU6JRWK=
D-247MG NXLTeoZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P2TGlEPTB;Nz6wOFM1PyEQvF2= NXLpT496W0GQR1XS
EW-18 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD1ZWZKSzVyPUeuNFczQTJizszN NGjKWWZUSU6JRWK=
KG-1 NV7R[XBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj1TWM2OD15Lk[yO|M5KM7:TR?= MlTyV2FPT0WU
REH MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG1fJVKSzVyPUeuOlgyODlizszN NX71dZlqW0GQR1XS
U-698-M MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfmVpZKSzVyPUeuPFQ{OTVizszN NV\LeJh1W0GQR1XS
KP-N-RT-BM-1 MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13yVmlEPTB;Nz65N|AzQSEQvF2= NV\uVHhtW0GQR1XS
MS-1 NF[3b|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHH0XmpKSzVyPUeuPVYxPDFizszN NIjGNmtUSU6JRWK=
SNU-C1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni1TWM2OD15Lkm4NVkzKM7:TR?= M1\Ze3NCVkeHUh?=
SK-MM-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDITWM2OD16LkK2NFY2KM7:TR?= M4DEPHNCVkeHUh?=
LAN-6 MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRThwM{CwNFEh|ryP MYLTRW5ITVJ?
NEC8 M1jjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF60WGRKSzVyPUiuN|A3QTFizszN NGLEVIJUSU6JRWK=
NCI-H1770 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRThwM{iwNFIh|ryP M1;abXNCVkeHUh?=
D-336MG NYGzTo9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{S3TmlEPTB;OD60NFEyPiEQvF2= MXLTRW5ITVJ?
COLO-829 NXfaTGpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPsTWM2OD16LkS4PFc6KM7:TR?= M{PTbnNCVkeHUh?=
LS-513 NGTXNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETCPIZKSzVyPUiuOVk2QTlizszN MnH1V2FPT0WU
YT NYO2fHFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXGPYNoUUN3ME24MlYzPDJ5IN88US=> NEXRSWlUSU6JRWK=
EW-24 NULWfm5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLy[nBbUUN3ME24Mlc3PTRizszN MYXTRW5ITVJ?
IST-SL1 M3P4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHqTWM2OD16Lki2OVQ{KM7:TR?= M37FU3NCVkeHUh?=
CA46 NIHtTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXzTWM2OD16Lkm1NFk5KM7:TR?= NYW2[ppIW0GQR1XS
NCI-H1838 NUHORY1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH5TWM2OD16Lkm4OlAzKM7:TR?= MWjTRW5ITVJ?
NCI-H719 NVfBelluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrtTWM2OD17LkK1Nlc6KM7:TR?= NXfmb49RW0GQR1XS
HCE-T NYXTZ|hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37pWWlEPTB;OT6zNFg2OSEQvF2= MWLTRW5ITVJ?
A498 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTlS3ZKSzVyPUmuN|YyOjRizszN NEjNRYRUSU6JRWK=
LB831-BLC NEP3XW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPQVY5kUUN3ME25Mlc3PTJzIN88US=> MV\TRW5ITVJ?
SKM-1 MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTlwOEW5OlMh|ryP MWfTRW5ITVJ?
THP-1 NXLoelgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXtTVhKSzVyPUmuPVY6OThizszN MX7TRW5ITVJ?
SHP-77 NWS5Z4E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjy[WJ6UUN3ME2xNE41ODdizszN MnThV2FPT0WU
EW-3 MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX4R4xTUUN3ME2xNE43Ojh7IN88US=> M1LHRXNCVkeHUh?=
KY821 NF\i[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFyLke2N{DPxE1? NWPaeYg6W0GQR1XS
NCI-SNU-1 M2jEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFzLkCyNVch|ryP MUDTRW5ITVJ?
HCC2218 NWqx[5ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;MSWlEPTB;MUGuN|k5PiEQvF2= NVfibmtuW0GQR1XS
IM-9 M{XWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfqN|ZKSzVyPUGxMlUyODZizszN MoCyV2FPT0WU
NCI-H889 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTBdVdKSzVyPUGxMlU{OTNizszN MWHTRW5ITVJ?
HDLM-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXSTWM2OD1zMj60NVU6KM7:TR?= NI\QWFZUSU6JRWK=
LB2518-MEL M13MRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTMTWM2OD1zMj62PFE2KM7:TR?= M4TCe3NCVkeHUh?=
NCI-H23 NYHRVFlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF|LkK0NlUh|ryP NIqzU3NUSU6JRWK=
NB17 M2jmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF|LkS1O|kh|ryP M2PBbnNCVkeHUh?=
NCI-H322M MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHkfFdKSzVyPUG0MlQxPjhizszN NGPxdGRUSU6JRWK=
SUP-T1 NIHnXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nDdWlEPTB;MUSuOFE{KM7:TR?= MWLTRW5ITVJ?
ES3 NFnFNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjlRWd3UUN3ME2xOU4xPzB|IN88US=> NFvhe5hUSU6JRWK=
ES5 NHnjNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjMeHhlUUN3ME2xOU4xPzh5IN88US=> NHu1ZoJUSU6JRWK=
NCI-H1650 NX:4flJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\JVVZKSzVyPUG1MlQ6PzlizszN MVPTRW5ITVJ?
NCI-H226 M2HlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fGSmlEPTB;MUWuPFc3QCEQvF2= NVvHZnRCW0GQR1XS
COR-L88 NXK3U2RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF4LkOxOEDPxE1? MVzTRW5ITVJ?
SCC-15 NHS2PXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LEXmlEPTB;MU[uN|g3QSEQvF2= MV7TRW5ITVJ?
GOTO NEnoWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrBeYpKSzVyPUG2MlQ4QTNizszN NHXCV2ZUSU6JRWK=
SIMA NVToXFE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LzZWlEPTB;MU[uOFgxOiEQvF2= Mn\rV2FPT0WU
NCI-H1299 NHnTfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H4dmlEPTB;MUeuNVU6OSEQvF2= M1u1bXNCVkeHUh?=
NCI-H1581 M3;HPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj2TWM2OD1zNz60NlE6KM7:TR?= MmruV2FPT0WU
MHH-NB-11 M2Kz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr6PIZKSzVyPUG3Mlk3QDNizszN MonnV2FPT0WU
MFM-223 M4HFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf3ZodKSzVyPUG4MlA2OzhizszN MnjYV2FPT0WU
ES7 M4HNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDJUWpmUUN3ME2xPE42PDNzIN88US=> M{TYdXNCVkeHUh?=
JVM-3 NEKzRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvpNIJXUUN3ME2xPE44OTdizszN NYLKc5UyW0GQR1XS
RL NEHGS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnYTWM2OD1{MD6zPFgh|ryP MVvTRW5ITVJ?
EC-GI-10 NITFcI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TONWlEPTB;MkGuNlA1OSEQvF2= NH;yXpRUSU6JRWK=
LNCaP-Clone-FGC NGi4XHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK3TWM2OD1{MT62O|Y5KM7:TR?= NEjENlJUSU6JRWK=
IMR-5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWruWlhOUUN3ME2yNU45PDl2IN88US=> NUjReIxJW0GQR1XS
KP-N-YS NGLscHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJzLki3OUDPxE1? MmS1V2FPT0WU
Mo-T NWrVUok3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;LeWlEPTB;MkKuNlE5PSEQvF2= MlPOV2FPT0WU
NCI-H128 NYHBUVBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjLd5FKSzVyPUKzMlU5PTNizszN MkfQV2FPT0WU
RH-1 MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv1bVJ2UUN3ME2yN{44QDZ4IN88US=> MVvTRW5ITVJ?
NCI-H2171 NHK0S4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MliwTWM2OD1{ND6yOFg2KM7:TR?= M{nRbnNCVkeHUh?=
RPMI-8866 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJ4Lke0NkDPxE1? M3\peHNCVkeHUh?=
SK-N-FI MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJ5LkO4NVEh|ryP MVfTRW5ITVJ?
LOXIMVI MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ5LkiwOVEh|ryP NGfxd4tUSU6JRWK=
P31-FUJ NX7vOohnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHrd4M{UUN3ME2zNU42Ozd2IN88US=> MkHKV2FPT0WU
KMS-12-PE M4HOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r2OmlEPTB;NEmuOVMxOiEQvF2= M3jVXXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID